Monte Carlo-based independent dose verification of radiosurgery HyperArc plans

Calvo-Ortega, J.F.; Moragues-Femenía, S.; Laosa-Bello, C.; Hermida-López, M.; Pozo-Massó, Miguel; Zamora-Pérez, Antonia

doi:10.1016/j.ejmp.2022.08.016

Cited by 7 publications

(8 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In general, a systematic underestimation was observed for the plans using 6 MV FFF energy. We suspect that this issue might be attributed to a slightly inexact modeling in PRIMO of the actual HD120 MLC, resulting in small differences in transmission and leakage, as we pointed out for 6 MV FFF beams from a TrueBeam equipped with a Millennium 120 MLC [ 19 ].…”

Section: Discussionmentioning

confidence: 99%

“…As a limitation, our study has not included verification of single-isocenter stereotactic radiosurgery plans for multiple brain metastases. This topic was previously investigated for 6 MV FFF beams and a Millennium 120 MLC, concluding that PRIMO can be used as secondary dose calculation software to check stereotactic radiosurgery plans from Eclipse [ 19 ]. Similar behavior should be expected for PRIMO and the HD120 MLC model.…”

Section: Discussionmentioning

confidence: 99%

“…Recently, the PRIMO MC software was validated by Calvo-Ortega et al as a tool for independent dose verification of HyperArc radiosurgery plans [ 19 ]. In that work, the phase-space files (PSFs) provided by Varian for 6 MV flattening-filter-free (FFF) photon beams from a Varian TrueBeam linear accelerator (linac) were used.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

PRIMO Monte Carlo software as a tool for commissioning of an external beam radiotherapy treatment planning system

Calvo-Ortega,

Hermida-López

2023

Rep Pract Oncol Radiother.

Self Cite

View full text Add to dashboard Cite

Background The purpose was to validate the PRIMO Monte Carlo software to be used during the commissioning of a treatment planning system (TPS). Materials and methods The Acuros XB v. 16.1 algorithm of the Eclipse was configured for 6 MV and 6 MV flattening-filter-free (FFF) photon beams, from a TrueBeam linac equipped with a high-definition 120-leaf multileaf collimator (MLC). PRIMO v. 0.3.64.1814 software was used with the phase space files provided by Varian and benchmarked against the reference dosimetry dataset published by the Imaging and Radiation Oncology Core–Houston (IROC-H). Thirty Eclipse clinical intensity-modulated radiation therapy (IMRT)/volumetric modulated arc therapy (VMAT) plans were verified in three ways: 1) using the PTW Octavius 4D (O4D) system; 2) the Varian Portal Dosimetry system and 3) the PRIMO software. Clinical validation of PRIMO was completed by comparing the simulated dose distributions on the O4D phantom against dose measurements for these 30 clinical plans. Agreement evaluations were performed using a 3% global/2 mm gamma index analysis. Results PRIMO simulations agreed with the benchmark IROC-H data within 2.0% for both energies. Gamma passing rates (GPRs) from the 30 clinical plan verifications were (6 MV/6MV FFF): 99.4% ± 0.5%/99.9% ± 0.1%, 99.8% ± 0.4%/98.9% ± 1.4%, 99.7% ± 0.4%/99.7% ± 0.4%, for the 1), 2) and 3) verification methods, respectively. Agreement between PRIMO simulations on the O4D phantom and 3D dose measurements resulted in GPRs of 97.9% ± 2.4%/99.7% ± 0.4%. Conclusion The PRIMO software is a valuable tool for dosimetric verification of clinical plans during the commissioning of the primary TPS.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

PRIMO Monte Carlo software as a tool for commissioning of an external beam radiotherapy treatment planning system

Calvo-Ortega,

Hermida-López

2023

Rep Pract Oncol Radiother.

Self Cite

View full text Add to dashboard Cite

show abstract

“…validated the HD120 MLC for VMAT plans. Other applications of PRIMO included the use of PRIMO as an independent tool for the beam commissioning of a 6 MV Varian Truebeam STx, 41 simulation of out‐of‐field dose, 42 simulation of conical collimators for stereotactic radiosurgery, 43 and the use of PRIMO as an independent dose verification system for radiosurgery HyperArc plans 44 …”

Section: Methodsmentioning

confidence: 99%

“…Other applications of PRIMO included the use of PRIMO as an independent tool for the beam commissioning of a 6 MV Varian Truebeam STx, 41 simulation of out-of -field dose, 42 simulation of conical collimators for stereotactic radiosurgery, 43 and the use of PRIMO as an independent dose verification system for radiosurgery HyperArc plans. 44 Table 1 summarizes the simulations details following the scheme proposed by the AAPM Task Group 268 report RECORDS. 45 PRIMO divides the dose simulation into three stages: the upper part of the linac, from the exit of the accelerating waveguide to a plane right above the secondary collimator jaws (stage s1).…”

Section: Primo Monte Carlo Simulationsmentioning

confidence: 99%

Validation of an in vivo transit dosimetry algorithm using Monte Carlo simulations and ionization chamber measurements

Sánchez‐Artuñedo,

Pié‐Padró,

Hermida‐López

et al. 2023

J Applied Clin Med Phys

View full text Add to dashboard Cite

PurposeTransit dosimetry is a safety tool based on the transit images acquired during treatment. Forward‐projection transit dosimetry software, as PerFRACTION, compares the transit images acquired with an expected image calculated from the DICOM plan, the CT, and the structure set. This work aims to validate PerFRACTION expected transit dose using PRIMO Monte Carlo simulations and ionization chamber measurements, and propose a methodology based on MPPG5a report.MethodsThe validation process was divided into three groups of tests according to MPPG5a: basic dose validation, IMRT dose validation, and heterogeneity correction validation. For the basic dose validation, the fields used were the nine fields needed to calibrate PerFRACTION and three jaws‐defined. For the IMRT dose validation, seven sweeping gaps fields, the MLC transmission and 29 IMRT fields from 10 breast treatment plans were measured. For the heterogeneity validation, the transit dose of these fields was studied using three phantoms: 10 , 30 , and a 3 cm cork slab placed between 10 cm of solid water. The PerFRACTION expected doses were compared with PRIMO Monte Carlo simulation results and ionization chamber measurements.ResultsUsing the 10 cm solid water phantom, for the basic validation fields, the root mean square (RMS) of the difference between PerFRACTION and PRIMO simulations was 0.6%. In the IMRT fields, the RMS of the difference was 1.2%. When comparing respect ionization chamber measurements, the RMS of the difference was 1.0% both for the basic and the IMRT validation. The average passing rate with a γ(2%/2 mm, TH = 20%) criterion between PRIMO dose distribution and PerFRACTION expected dose was 96.0% ± 5.8%.ConclusionWe validated PerFRACTION calculated transit dose with PRIMO Monte Carlo and ionization chamber measurements adapting the methodology of the MMPG5a report. The methodology presented can be applied to validate other forward‐projection transit dosimetry software.

show abstract

Independent Monte Carlo dose calculation identifies single isocenter multi‐target radiosurgery targets most likely to fail pre‐treatment measurement

Erickson,

Cui,

Alber

et al. 2024

J Applied Clin Med Phys

View full text Add to dashboard Cite

PurposeFor individual targets of single isocenter multi‐target (SIMT) Stereotactic radiosurgery (SRS), we assess dose difference between the treatment planning system (TPS) and independent Monte Carlo (MC), and demonstrate persistence into the pre‐treatment Quality Assurance (QA) measurement.MethodsTreatment plans from 31 SIMT SRS patients were recalculated in a series of scenarios designed to investigate sources of discrepancy between TPS and independent MC. Targets with > 5% discrepancy in DMean[Gy] after progressing through all scenarios were measured with SRS MapCHECK. A matched pair analysis was performed comparing SRS MapCHECK results for these targets with matched targets having similar characteristics (volume & distance from isocenter) but no such MC dose discrepancy.ResultsOf 217 targets analyzed, individual target mean dose (DMean[Gy]) fell outside a 5% threshold for 28 and 24 targets before and after removing tissue heterogeneity effects, respectively, while only 5 exceeded the threshold after removing effect of patient geometry (via calculation on StereoPHAN geometry). Significant factors affecting agreement between the TPS and MC included target distance from isocenter (0.83% decrease in DMean[Gy] per 2 cm), volume (0.15% increase per cc), and degree of plan modulation (0.37% increase per 0.01 increase in modulation complexity score). SRS MapCHECK measurement had better agreement with MC than with TPS (2%/1 mm / 10% threshold gamma pass rate (GPR) = 99.4 ± 1.9% vs. 93.1 ± 13.9%, respectively). In the matched pair analysis, targets exceeding 5% for MC versus TPS also had larger discrepancies between TPS and measurement with no GPR (2%/1 mm / 10% threshold) exceeding 90% (71.5% ± 16.1%); whereas GPR was high for matched targets with no such MC versus TPS difference (96.5% ± 3.3%, p = 0.01).ConclusionsIndependent MC complements pre‐treatment QA measurement for SIMT SRS by identifying problematic individual targets prior to pre‐treatment measurement, thus enabling plan modifications earlier in the planning process and guiding selection of targets for pre‐treatment QA measurement.

show abstract

Monte Carlo-based independent dose verification of radiosurgery HyperArc plans

Cited by 7 publications

References 47 publications

PRIMO Monte Carlo software as a tool for commissioning of an external beam radiotherapy treatment planning system

PRIMO Monte Carlo software as a tool for commissioning of an external beam radiotherapy treatment planning system

Validation of an in vivo transit dosimetry algorithm using Monte Carlo simulations and ionization chamber measurements

Independent Monte Carlo dose calculation identifies single isocenter multi‐target radiosurgery targets most likely to fail pre‐treatment measurement

Contact Info

Product

Resources

About